Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Cash from Operations (2021 - 2025)

Kezar Life Sciences' Cash from Operations history spans 5 years, with the latest figure at 9830000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 43.81% year-over-year to 9830000.0; the TTM value through Sep 2025 reached 56640000.0, up 25.83%, while the annual FY2024 figure was 74212000.0, 9.1% up from the prior year.
  • Cash from Operations for Q3 2025 was 9830000.0 at Kezar Life Sciences, up from 12795000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 8357000.0 in Q1 2021 and bottomed at 22862000.0 in Q1 2024.
  • The 5-year median for Cash from Operations is 16360000.0 (2022), against an average of 15629210.53.
  • The largest annual shift saw Cash from Operations plummeted 64.36% in 2022 before it surged 43.81% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 11081000.0 in 2021, then plummeted by 43.34% to 15883000.0 in 2022, then fell by 19.5% to 18980000.0 in 2023, then rose by 11.35% to 16825000.0 in 2024, then soared by 41.58% to 9830000.0 in 2025.
  • Per Business Quant, the three most recent readings for KZR's Cash from Operations are 9830000.0 (Q3 2025), 12795000.0 (Q2 2025), and 17190000.0 (Q1 2025).